Advertisement

A Functional Assay to Determine the Capacity of Oncolytic Viruses to Induce Immunogenic Tumor Cell Death

Protocol
First Online:
  • 1.6k Downloads
Part of the Methods in Molecular Biology book series (MIMB, volume 2058)

Abstract

Oncolytic immunotherapy efficacy relies partially on the induction of immunogenic tumor cell death following infection with oncolytic viruses (OV) to induce an antitumor immune response. Here, we describe a method to determine if an OV is able to induce such an immunogenic tumor cell death. This method consists in testing whether tumor cells lysed by an OV are able to induce the maturation of human monocyte-derived immature dendritic cells (Mo-iDC).

Key words

Antigen-presenting cells Dendritic cells Immunogenic cell death Oncolytic viruses Flow cytometry 
This is a preview of subscription content, log in to check access.

References

  1. 1.
    Lichty BD, Breitbach CJ, Stojdl DF, Bell JC (2014) Going viral with cancer immunotherapy. Nat Rev Cancer 14(8):559–567.  https://doi.org/10.1038/nrc3770CrossRefPubMedGoogle Scholar
  2. 2.
    Gauvrit A, Brandler S, Sapede-Peroz C, Boisgerault N, Tangy F, Gregoire M (2008) Measles virus induces oncolysis of mesothelioma cells and allows dendritic cells to cross-prime tumor-specific CD8 response. Cancer Res 68(12):4882–4892.  https://doi.org/10.1158/0008-5472.can-07-6265CrossRefPubMedGoogle Scholar
  3. 3.
    Donnelly OG, Errington-Mais F, Steele L, Hadac E, Jennings V, Scott K, Peach H, Phillips RM, Bond J, Pandha H, Harrington K, Vile R, Russell S, Selby P, Melcher AA (2013) Measles virus causes immunogenic cell death in human melanoma. Gene Ther 20(1):7–15.  https://doi.org/10.1038/gt.2011.205CrossRefPubMedGoogle Scholar
  4. 4.
    Achard C, Guillerme JB, Bruni D, Boisgerault N, Combredet C, Tangy F, Jouvenet N, Gregoire M, Fonteneau JF (2017) Oncolytic measles virus induces tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)-mediated cytotoxicity by human myeloid and plasmacytoid dendritic cells. Oncoimmunology 6(1):e1261240.  https://doi.org/10.1080/2162402x.2016.1261240CrossRefPubMedGoogle Scholar
  5. 5.
    Fonteneau JF, Guillerme JB, Tangy F, Gregoire M (2013) Attenuated measles virus used as an oncolytic virus activates myeloid and plasmacytoid dendritic cells. Oncoimmunology 2(5):e24212.  https://doi.org/10.4161/onci.24212CrossRefPubMedPubMedCentralGoogle Scholar
  6. 6.
    Guillerme JB, Boisgerault N, Roulois D, Menager J, Combredet C, Tangy F, Fonteneau JF, Gregoire M (2013) Measles virus vaccine-infected tumor cells induce tumor antigen cross-presentation by human plasmacytoid dendritic cells. Clin Cancer Res 19(5):1147–1158.  https://doi.org/10.1158/1078-0432.ccr-12-2733CrossRefPubMedGoogle Scholar
  7. 7.
    Royer PJ, Tanguy-Royer S, Ebstein F, Sapede C, Simon T, Barbieux I, Oger R, Gregoire M (2006) Culture medium and protein supplementation in the generation and maturation of dendritic cells. Scand J Immunol 63(6):401–409.  https://doi.org/10.1111/j.1365-3083.2006.001757.xCrossRefPubMedGoogle Scholar
  8. 8.
    Coulais D, Panterne C, Fonteneau JF, Gregoire M (2012) Purification of circulating plasmacytoid dendritic cells using counterflow centrifugal elutriation and immunomagnetic beads. Cytotherapy 14(7):887–896.  https://doi.org/10.3109/14653249.2012.689129CrossRefPubMedGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC, part of Springer Nature 2020

Authors and Affiliations

  1. 1.CRCINA, INSERM, Université d’Angers, Université de NantesNantesFrance
  2. 2.Immunology Graft OncologyLabex IGONantesFrance
  3. 3.CNRS 3569, Institut PasteurParisFrance

Personalised recommendations

Cite protocol

Buy options